
The Chemours Company
- Jurisdiction
United States - LEI
549300M1BOLNXL8DOV14 - ISIN
US1638511089 (CC )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€56.73 323.1% undervalued - Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. Read full profile
Fundamentals
- Net revenue
€5.01B - Gross margin
18.3% - EBIT
€75.06M - EBIT margin
1.5% - Net income
-€358.24M - Net margin
-7.1%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
N/A | N/A |
Stock price
Dividends
- Last dividend amount
-
$0.09 - Ex date
-
- Payment date
-
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Dignam Denise | President & CEO |
|
|
|
|
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 1, 2024 (Q1 2024)